Resultados: 3

    CARI Guidelines: urate-lowering treatment in early CKD

    The scope of the guideline is urate-lowering therapy in patients with chronic kidney disease (not on dialysis) without symptomatic hyperuricemia (such as gout and/or uric acid stone formation). The guideline does not make recommendations about the management of uric-acid kidney stones or gout in people w...

    Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence

    Kidney int; 102 (5), 2022
    The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD) represents a focused update of the KDIGO 2020 guideline on the topic. The guideline targets a broad audience of clinicians treating people with diabetes and CKD. ...

    Recommendations for the diagnosis and management of Fabry disease in pediatric patients: a document from the Rare Diseases Committee of the Brazilian Society of Nephrology (Comdora-SBN)

    J. bras. nefrol; 44 (2), 2022
    Fabry disease (FD) is a genetic disease, with X-chromosome linked inheritance, due to variants in the GLA gene that encodes the α-galactosidase A (α-GAL) enzyme. The purpose of the present study was to create a consensus aiming to standardize the recommendations regarding the renal involvement of FD wi...